All posts by imreal

Dan Fairfax Joins StorCentric Board of Advisors


News Image

StorCentric, a global provider of world-class and award-winning storage solutions, today announced it has added Dan Fairfax to its Board of Advisors. Fairfax brings over 25 years of technology experience, including executive roles at Brocade Communications Systems, acquired by Broadcom in 2017, and currently serves on the Board of Directors at Super Micro Computer, Saama Technologies, and Energous.

“I am extremely pleased to welcome someone of Dan’s caliber to the team. His business acumen, particularly his finance background, will be instrumental as we accelerate our growth strategy with both product innovation and acquisitions,” said Mihir Shah, CEO, StorCentric. “We are committed to providing our customers the solutions to access, manage and protect their digital information. Dan joins us during a pivotal time as we introduce new solutions to market and capitalize on our software and hardware expertise to address the astonishing levels of data growth.”

StorCentric recently introduced several new products including high density QLC-based solutions designed to deliver enhanced performance and unbeatable economics for the most demanding enterprise platforms.

“I am honored to have been invited to join StorCentric’s Board of Advisors,” said Fairfax. “StorCentric has garnered the attention of the storage industry in a very short period of time with a rapid pace of four acquisitions in the past two years, and is seen as a trusted storage solutions provider with its reputable Drobo, Nexsan, Retrospect and Vexata brands. StorCentric provides a broad set of data management solutions with world-class products, IP, and professional expertise focused on helping customers scale their businesses, and I am excited to be part of this journey.”

Fairfax served as Senior Vice President and Chief Financial Officer of Brocade Communications from June 2011 to November 2017. Fairfax previously served as Brocade’s Vice President of Global Services from August 2009 to June 2011 and Brocade’s Vice President of Business Operations from January 2009 to August 2009. Prior to Brocade, Fairfax served as Chief Financial Officer of Foundry Networks, Inc. from January 2007 until December 2008. Prior to joining Foundry Networks, Fairfax served as the CFO at a number of technology companies, including GoRemote Internet Communications, Ironside Technologies, Inc., ACTA Technology, and NeoVista Software. Before those appointments, he held a variety of senior financial management and operations positions at Siemens and Spectra-Physics.

Fairfax holds an MBA from The University of Chicago Booth School of Business and a Bachelor of Arts degree in economics from Whitman College. Additionally, Fairfax is a certified public accountant in the state of California with an inactive license.

Tweet this: @StorCentric Adds Finance & Operations Leader Dan Fairfax to Board of Advisors (BOA) http://www.storcentric.com @Nexsan @Drobo @RetrospectInc @Vexata

About StorCentric

StorCentric provides world-class and award-winning storage solutions. Between its Drobo, Nexsan®, Retrospect and Vexata divisions, the company has shipped over 1M storage solutions and has won over 100 awards for technology innovation and service excellence. StorCentric innovation is centered around customers and their specific data requirements, and delivers quality solutions with unprecedented flexibility, data protection, performance and expandability. For further information, please visit: http://www.storcentric.com.

Share article on social media or email:

EnsoData Accelerates Analysis of Human Health, Improving Diagnostic Accuracy and Saving Hospitals Significant Time and Money


News Image

“Sleep apnea is a condition that plagues nearly one billion people worldwide, and we’re uniquely positioned to address this massive problem. We know that not everyone has access to quality and affordable treatment, and have the conviction that our technology can help bridge that gap.”

EnsoData, the company simplifying the process for analyzing the human body to accurately diagnose health conditions, today announces $9 million Series A financing led by Venture Investors and Zetta Venture Partners. Using artificial intelligence, EnsoData’s technology transforms billions of waveform data points collected from sensors in medical devices and wearables into an easy-to-read report, so clinicians can make faster, more accurate diagnoses.

Waveforms are used in healthcare to diagnose, monitor, and treat patients. Heartbeats on an EKG, eye movements through an EOG, and brain waves through an EEG all output as waveform data, with over 1.5 billion waveforms run per year globally across specialties. EnsoData leads the world in reading and understanding these waveforms, starting with sleep.

“Sleep apnea is a condition that plagues nearly one billion people worldwide, and we’re uniquely positioned to address this massive problem,” said Chris Fernandez, CEO of EnsoData. “We know that not everyone has access to quality and affordable treatment, and have the conviction that our technology can help bridge that gap. Automating waveform data analysis saves clinicians significant time, and labs and healthcare systems significant money, so they can focus on what really matters — the patients and what’s literally keeping them up at night.”

Why Start with Sleep?

People spend between one-third and one-quarter of their time on earth asleep, yet only recently did we begin to study its profound impact on our overall health and happiness. Sleep apnea is associated with increased risk for high blood pressure, heart problems, diabetes, depression, liver problems, complications with medications, surgeries, pregnancies, and issues with bed partners. It affects millions of Americans and costs the US nearly $150B per year — yet 80 percent of patients go undiagnosed and untreated. By analyzing the waveforms found in sleep studies, EnsoData is able to accurately detect and diagnose sleep apnea and its related conditions — at a drastically reduced cost and in substantially less time.

“We believe that EnsoData will be a game-changer for the way we diagnose and treat patients,” said Mark Gorenberg, Managing Director at Zetta Venture Partners. “Sleep is just the beginning. Waveform AI may be the lowest cost, most scalable, and most widely available tool for diagnosing patients. It will seriously advance our understanding of health and the human body.”

How It Works

EnsoData is the first artificial intelligence technology cleared to aid clinicians in the diagnosis of sleep disorders and sleep apnea. By analyzing billions of waveform data points, it quickly finds patterns and events for clinical diagnosis, replacing a workflow that requires hours from clinicians to manually mark reams of complex data by hand.

EnsoData partners with top clinicians, health systems, and academic medical centers to improve healthcare outcomes by streamlining data analysis with Waveform AI.

In addition to Zetta Venture Partners and Venture Investors, the round was filled out by a syndicate of institutional investors from across the country, including SleepScore Ventures, Dreamit Ventures, and Necessary Ventures. The Series A participants join Series Seed investors Colle Capital, HealthX Ventures, Sternhill Associates, as well as board of directors members Justin Mortara, PhD and Dr. Fred Robertson, MD.

The capital will be used to launch new AI products in sleep and neurology; grow the company’s world-class team; expand diagnostic access and partnerships with leading sleep clinics, enterprise health systems, academic medical centers, home sleep testing providers, and integrated diagnostic testing facilities; and extend support for clinical trials that enable patient access to a new generation of effective, personalized medications and therapeutic devices.

“We’ve known Chris and the founders since their collegiate years and have always believed in them and the potential for AI to analyze medical waveform data,” said Scott Button, Managing Director of Venture Investors. “EnsoData has all the characteristics of a disruptive, breakthrough technology. It increases access, improves outcomes and enhances patient and physician satisfaction while at the same time reducing cost. We believe its Waveform AI will help to create a new gold standard of care, and we’re thrilled to be a part of this incredible journey to uncovering diagnostics hidden in waveforms — for those suffering from sleep disorders and beyond.”

# # #

ABOUT ENSODATA

EnsoData simplifies the process for reading and analyzing the human body to quickly and accurately diagnose conditions, starting with sleep. Using artificial intelligence, EnsoData’s technology analyzes billions of data points collected from sensors placed throughout the entire human body to deliver the most accurate diagnoses in an easy-to-read report for clinicians. Heartbeats on an EKG, eye movements through an EOG, and brain waves through an EEG all output as waveform data; EnsoData leads the world in reading and understanding waveforms. Learn more at ensodata.com.

Share article on social media or email:

“Committing to Look in the Mirror, and Walk in the Light”


NACDS stands among those committed to peering into the dimmest reaches of our own souls, for the purpose of transforming ourselves into an ever-more-reverent steward of our nation’s brightest ideals and an ever-more-caring servant of all humanity.

National Association of Chain Drug Stores (NACDS) President and CEO Steven C. Anderson issued the following op-ed today:

On May 25, George Floyd’s breath was taken from him tragically and senselessly. Many Americans feel that their breath was taken along with his. For many others, George Floyd’s life has passed into a deeper consciousness of the realities faced by Black Americans – realities that have been too easy to disregard.

George Floyd’s family said that his killing was caused by a pandemic of racism and discrimination. Maybe this is a unique and timely comparison that can sink in. After all, over the past three months, our nation has feared a virus that spreads quickly, that affects its victims harshly and unpredictably, and that can pass from a carrier who is not even aware of his or her infection. That sounds like racism and discrimination to me.

Standing Together

As is the case across business settings, we recognize that people of color on our pharmacy teams may feel heartbroken, numb or exhausted as a result of the most recent tragedies involving George Floyd and others. The same is true of the diverse customers whom they serve.

Individuals and entities are considering this issue from their own perspectives, and the National Association of Chain Drug Stores (NACDS) is among the organizations doing so. Like those who have gathered in great numbers peacefully yet passionately, we stand committed to confronting racism and discrimination.

True leaders like Martin Luther King, Jr. taught us to confront our disappointment and anger with perseverance and hope. What will it take for us to validate his vision that “only in the darkness can you see the stars”?

Every individual and every organization will need to consider and answer that question for themselves. For NACDS, it may be helpful to think of the role that we can play in terms of our vision that pharmacies serve as the face of neighborhood healthcare. That vision relates directly to the individuals and communities we serve and to the individuals who serve as team members in our members’ pharmacies.

A Commitment to Listen

First, however, NACDS must look in the mirror. Like any other organization or individual, we must acknowledge what we may not yet know and understand fully. Listening is an important treatment for the racial divide. As a member-driven trade association, and as an organization committed to empowering our own staff team to thrive, NACDS will pursue important initiatives. These initiatives are designed to make the topics of diversity and inclusion ubiquitous within the Association.

NACDS will create a Diversity and Inclusion Council that consists of representatives from our member companies. Participants will include companies’ diversity and inclusion officers and other interested personnel. The NACDS Diversity and Inclusion Council will make recommendations to NACDS as it deems appropriate, and it also will help to share knowledge among members of this crucial subject matter.

NACDS also will create a Diversity and Inclusion Team among the NACDS staff. Reflecting the approach of our member companies, NACDS already has put into place policies that are important for protecting all employees. NACDS also seeks to create a positive culture for all. However, we need to continue to challenge ourselves to make further evaluations about what more we can do to be the kind of organization that we must be. We will look to the Diversity and Inclusion Team to help to accomplish that.

In addition to these important initiatives, NACDS anticipates a related announcement in the coming weeks that will further bolster our work in this important area. This announcement will relate to our engagement with an external force whose critical eye, authenticity, and proven experience will add tremendous power to this advancement of diversity and inclusion within NACDS.

Pharmacies as the Face of Neighborhood Healthcare: Our Communities

Regarding the communities that pharmacies serve, NACDS members already help to address healthcare disparities within the nation, and we will identify opportunities by which NACDS can help to redouble these efforts. The fact that the current discussions of race are occurring amid the COVID-19 pandemic is timely, as we are learning that Black Americans are disproportionately affected by the virus. This reflects a deeper divide which also can be seen in disparities related to chronic conditions.

To achieve success in the next phase of our nation’s journey in confronting COVID-19, an NACDS report – “Pharmacies: A Vital Partner in Reopening America” – emphasizes the importance of meeting the needs of the medically underserved. The report includes recommendations regarding testing and the availability of treatments and vaccines when they become available, and these recommendations include a specific focus on those in the most need.

Similarly, NACDS has made it a priority to serve as a thought leader in addressing social determinants of health and to collaborate in federal efforts to help address disparities in care, and to engage with the Centers for Disease Control and Prevention to address social determinants of health.

We raise these examples not to suggest that they are in any way sufficient, but rather to give hope that a renewed effort is not starting from scratch. Together, we can and must do more.

Pharmacies as the Face of Neighborhood Healthcare: Our Team Members

Regarding the individuals who serve as team members in our members’ pharmacies, the NACDS Foundation – which is affiliated with NACDS – is committed to fostering the commitment to diversity and inclusion that is ingrained in the pharmacy community. In 2017, the NACDS Foundation initiated as part of its scholarship program a new category of diversity and inclusion scholarships which focuses on helping people of color to succeed. Through this initiative, the NACDS Foundation has funded projects proposed by colleges and schools of pharmacy that include targeted engagement with Historically Black Colleges and Universities; outreach to high school students who demonstrate interest in pursuing a pharmacy education; supplemental training to empower student pharmacists in preparation for their pharmacy education and during their coursework; peer mentoring; and more.

Now, it is more important than ever before to build on this endeavor. We are committed to doing that.

Martin Luther King, Jr. said that each of us must choose whether to “walk in the light of creative altruism or in the darkness of destructive selfishness.” NACDS stands among those committed to peering into the dimmest reaches of our own souls, for the purpose of transforming ourselves into an ever-more-reverent steward of our nation’s brightest ideals and an ever-more-caring servant of all humanity.

Share article on social media or email:

Maestro Health finds 42% of people say mental health inhibits them from performing well in their jobs


News Image

Maestro Health, a tech-enabled health and benefits TPA, just announced the release of its Mental Health Stigma in the Workplace survey which examines the state of employees’ mental health and how employers are addressing it. The report is based on a survey of more than 2,000 U.S. workers and was collected in March 2020.

Maestro Health found 63% of employees have struggled with a mental health condition at some point in their lives; 42% said their condition has a significant impact on their ability to do their job well. Yet, just over half (51%) of those surveyed aren’t comfortable talking to their manager about their challenges, highlighting the need for employers to break the stigma around mental health in the workplace.

“The spotlight that is now on mental health is long overdue, and it’s up to employers, healthcare providers and health plans to move the needle on mental wellbeing communication, education and support services available in and out of the workplace,” said Nancy Reardon, Chief Strategy and Product Officer at Maestro Health. “Every component of wellbeing, whether it’s mental, physical, emotional, social or financial, has an impact on an individual’s overall health. By ensuring that benefits and educational marketing strategies prioritize overall wellbeing, employers will eventually see healthier workforces, lower healthcare costs and improved productivity. But if our survey is any indication, there is still a lot of work to be done to realize those benefits.”

The survey also examined work-related stress and how well employers educate their workforce about stress and signs of burnout. Key findings include:

  • 56% of employees have not received information about mental health from their employers.
  • 51% experience work-related stress on a weekly basis, while more than one-third experience it daily.
  • 60% have taken a day off strictly because of work-related stress.
  • 69% have experienced burnout as a result of their job, with employees in media, healthcare and food industries having reported experiencing the most burnout.

Mental health education doesn’t just apply in times of crisis or during open enrollment. It is important we stop separating the mind from the body. Proactively preparing your workforce for future mental health-related issues can prevent employees from experiencing increased fear of the unknown because they are equipped with information and support that can help them better navigate stressors like benefit costs, where to go for doctor visits and which mental health counselors are in their network. By providing continuous open communication about what services are available for employees, how they can access those services and what they will cost, employers have an opportunity to change the narrative and remove the stigma surrounding overall mental health.

“It shouldn’t take a crisis for company leaders to put mental wellbeing at the forefront, but now more than ever, employers should be working to ensure their employees have what they need to be well,” said Craig Maloney, Maestro Health’s Chief Executive Officer. “Maestro Health helps employers empower their employees to take control of their health and wellbeing, and we’ve built this mentality into our own culture. As a tech-enabled health and benefits TPA, we provide the support and resources employees need to improve both their physical and mental health outcomes—which benefits everyone.”

For more information about how Maestro Health helps organizations address mental health in the workplace, please visit: http://www.maestrohealth.com.

About Maestro Health™

Maestro Health works with employers and their trusted advisers to administer self-funded health plans. By blending technology, analytics, care management and administrative services, Maestro Health helps employers optimize their health plans, drive better health outcomes and lower costs. When partnering with Maestro Health, employers can save money on employee healthcare and focus on what really matters—their people.

To learn more, visit: http://www.maestrohealth.com.

Share article on social media or email:

U.S. EP Labs Losing $500 Million Each Year Due to Underutilized Reprocessing Programs


The average EP lab today only realizes about 35 percent of the reprocessing savings potential, leaving nearly half a billion dollars in savings on the table.

Innovative Health, Inc. today released a new economic analysis that revealed today’s electrophysiology (EP) labs are missing out on an estimated $500 million in savings each year due to underutilization of reprocessing in Atrial Fibrillation (AFib) and other catheter ablation procedures. The analysis, presented in the company’s new whitepaper, “EP Single-Use Device Reprocessing by the Numbers,” notes that fuller implementation of single-use device reprocessing programs could provide the economic infusion into the hospital supply chain needed to help offset recent losses due to the COVID-19 pandemic.

“The high costs of single-use devices used in catheter ablation procedures puts severe strain on the economics of an EP lab,” said Innovative Health CEO Rick Ferreira. “Using reprocessed single-use devices in ablation procedures can dramatically reduce the costs of catheter ablation, especially in AFib procedures, where the most expensive devices are used. In fact, U.S. healthcare can reduce device costs in AFib procedures by approximately $728 million per year if single-use device reprocessing is fully utilized. When other catheter ablations are included, total potential savings increase to $773 million. Unfortunately, the average EP lab today only realizes about 35 percent of the reprocessing savings potential, leaving nearly half a billion dollars in savings on the table.”

Additional key findings of Innovative Health’s first-of-its-kind analysis include the following:


  • In 2020, there will be more than 360,000 ablation procedures in the U.S., and more than two-thirds of these (240,000) are AFib procedures.
  • This year, U.S. hospitals will spend more than $2.5 billion on devices used in AFib procedures. That number increases to more than $3.1 billion when including other catheter ablation procedures.
  • Device costs in AFib procedures are approximately $10,500 per procedure. Some of the devices used are very expensive, with ablation catheters (~$3,456), ICE catheters (~$2,650) and mapping catheters (~$1,750) making up 75 percent of procedure device costs.
  • When replacing new mapping catheters and ICE catheters with reprocessed ones, costs are reduced by approximately $2,200 per procedure.
  • Hospitals get paid approximately $20,690 for each AFib procedure. However, device costs are still more than half of the reimbursement amount, which is generally considered unsustainable for any hospital activity. Using reprocessed single-use devices instead of new drives device costs down to approximately 36 percent of reimbursement.

“In 2019, the average U.S. hospital had an operating margin of around 2 percent. According to Modern Healthcare, by March 2020, the average hospital had a year-to-date operating margin of -8 percent,” Ferreira added. “In the current economic climate, single-use device reprocessing must be part of the supply chain strategy, and it’s our hope that this new economic analysis and whitepaper will give hospital administrators the information they need to ensure their reprocessing programs are leveraged for maximum savings.”

Administrators and clinicians can learn more and download the full whitepaper here.

About Innovative Health

Innovative Health is an advanced medical device reprocessing company that offers smarter utilization of medical devices in hospitals’ cardiology and electrophysiology programs.

Share article on social media or email:

Language Scientific and Clinical Outcomes at Oxford University Innovation Announce Collaboration for Translation, Linguistic Validation and COA Management Services


Language Scientific is always looking to collaborate with highly respected organizations that put quality first such as Oxford University Innovation.

Language Scientific, Inc., the leading medical and scientific translation company, is pleased to announce a new innovative collaboration with Oxford University Innovation Ltd, the premier provider of Clinical Outcome Assessment (COA) management services. This strategic collaboration will allow for COA copyright owners and authors to reduce the time they spend managing health outcome measures as well as enable their instruments to be widely used in global study sites through robust translation, linguistic validation and cognitive debriefing of clinical questionnaires.

Reaching the widest possible audience whilst protecting the integrity of the instrument can be difficult when managing a COA instrument in house. It can become burdensome keeping track of users, licensees, translations, platforms and unauthorized or improper use of your COA. The Clinical Outcomes Team at Oxford University Innovation (The University of Oxford’s wholly owned technology transfer company) specializes in the dedicated, world class professional management of COA Instruments. They offer industry leading expertise assisting with COA development through their experience in managing all aspects of the licensing process, user support and comprehensive creative marketing.

Language Scientific’s experienced project managers, certified translators, in-country investigators, clinicians, psychologists, linguists and other professionals, combined with ISO 9001:2015 and ISO 17100:2015 certified processes, ensure that the linguistic validation of COAs and eCOAs are both culturally appropriate and conceptually equivalent. Language Scientific’s Linguistic Validation services verify that translations of all items are interpreted in the same way across target populations and regions and have the same content validity. This ensures that measurement properties of the items will be the same across different language versions of the instrument and that data can be validly pooled across international sites and that the process will meet FDA and EMEA guidelines.

Oxford University Innovation is collaborating with Language Scientific to provide linguistic validation and translation services because of LS’ extensive experience and highest quality reputation in assisting clinical, medical and scientific organizations. Language Scientific has over 20 years of experience providing clinical translation, linguistic validation and cognitive debriefing services in over 215 languages to customers such as Amgen, Merck Healthcare KGaA, Eli Lilly, Intercept Pharmaceuticals, Novo Nordisk and Roche. Their team of industry expert linguists and clinicians reside in over 120 countries and are assigned to a project based on their experience in the appropriate therapeutic area.

“At Language Scientific, we craft unique solutions for leading pharmaceutical companies and universities. This has enabled us to create a successful linguistic validation practice focused on providing the highest quality service to our customers” says LS CEO Sharon Blank. “By leveraging our native speaking medical professional linguists, we are able to provide the highest quality translations for our partners. Language Scientific is always looking to collaborate with highly respected organizations that put quality first such as Oxford University Innovation. I am thrilled to be announcing our partnership and look forward to leveraging our extensive Linguistic Validation and Cognitive Debriefing experience.”

“The Clinical Outcomes team at Oxford University Innovation prides itself on providing the highest quality services for our clients, so I was very pleased to find a delivery partner in Language Scientific who share our passion for quality in service delivery” says Dr. David Churchman Clinical Outcomes – Business Manager. “I am really pleased to be able to offer our clients the services of a highly specialized company such as Language Scientific, that puts the high quality of their translations first and foremost.”

About Language Scientific, Inc. ®

Language Scientific, Inc. is a US-based globalization company specializing in clinical, medical, scientific and technical language and linguistic validation services and solutions with a record of more than 20 years of excellence in over 215 languages. Language Scientific serves more than 1,500 clients in the pharmaceutical, clinical, and medical device industries, from Fortune 500 companies to small emerging companies. Our specialization, focus, innovation and customer-centered attitude have earned us the trust of many of the world’s leading life sciences companies. For more information, visit: https://www.languagescientific.com or email: info@languagescientific.com.

Certifications

ISO 9001:2008

ISO 17100:2015

https://www.languagescientific.com

About Oxford University Innovation Ltd.

Clinical Outcomes (at Oxford University Innovation) is a UK-based company, solely owned by the University of Oxford, specializing in the management and support of high-quality Clinical Outcome Assessments. The Clinical Outcomes team has been active in supporting COA users for over 14 years and represents the wishes of COA developers from within academia, healthcare providers and commercial organizations. Our international clients, which includes over 750 new users every year, covers the healthcare spectrum including academic research, publicly and independently funded healthcare providers, medical device companies and the pharmaceutical sector. For more information, visit https://innovation.ox.ac.uk/clinical-outcomes/ or email healthoutcomes@innovation.ox.ac.uk.

Share article on social media or email:

Study of SAC’s Role in Multiple Myeloma and Erythropoietin-Induced Osteoporosis


CBHI and UAMS Collaborative Research

While we have had amazing recovery cases of patients with multiple myeloma undergoing SAC therapy, the collaborative research will help us to gain a deeper understanding of the healing pathways of SAC for multiple myeloma and erythropoietin-induced osteoporosis.

Calcium & Bone Health Institute (CBHI) and the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute announced that they are engaged in collaborative research to study the efficacy of Sigma Anti-bonding Calcium (SAC) as a treatment option for patients with multiple myeloma and erythropoietin-included osteoporosis.

“We are truly excited to work with the University of Arkansas, which has the most comprehensive center in the world of research and clinical care related to multiple myeloma,” said Dr. Paul Lee, the president of CBHI. “While we have had amazing recovery cases of patients with multiple myeloma undergoing SAC therapy, the collaborative research will help us to gain a deeper understanding of the healing pathways of SAC for multiple myeloma and erythropoietin-induced osteoporosis.”

Multiple myeloma is the second most common hematological malignancy. It mostly occurs at older ages and remains an incurable disease. It is a B cell cancer mainly characterized by the proliferation of malignant plasma cells in the bone marrow, the presence of monoclonal serum immunoglobulin, and osteolytic lesions. Multiple myeloma is highly associated with bone destruction, where osteoclasts are more active than osteoblasts. Studies have found that myeloma progresses with osteoclast induced bone resorption while osteoblast enhanced bone formation inhibits the progression. This evidence indicates that SAC’s effect on regulating the activities of osteoclasts and osteoblasts poses itself as a good candidate for myeloma therapy.

SAC (Sigma Anti-Bonding Calcium) calcium was invented by Dr. Paul Lee of CBHI in 2009. Utilizing unstable sigma-antibonding in calcium carbonate molecules, SAC readily releases calcium to be absorbed directly in ionic form without the help of vitamin D and peptides. A small amount of this physiologically active form of calcium triggers hormonal responses to restore calcium homeostasis, a crucial balance responsible for healthy mitochondrial function and correct cellular signaling in activating natural healing mechanisms. SAC’s healing pathways are natural without side effects.

This two-year collaborative research focuses on pharmacokinetics study of SAC, biological safety of SAC, and in vivo effects of SAC in multiple myeloma and erythropoietin-induced osteoporosis.

About CBHI

Calcium and Bone Health Institute (CBHI) is a nonprofit scientific research organization based in Canada. With the invention of novel SAC ionic calcium carbonate, its primary research focuses on the role of ionic calcium in treating over 150 calcium-related chronic degenerative diseases such as osteoporosis, arthritis, Alzheimer’s, metabolic diseases, etc. By conducting laboratory and clinical research, CBHI endeavors to find effective prevention and treatment methods. CBHI collaborates with many other research centers such as SFU, UBC, UC Davis, NSERC Canada, and BC Government to combine the research with fundamental sciences such as mathematics, chemistry, physics, and biology. It held the first International Sigma Anti-Bonding Calcium Symposium (ISACS) 2019 in Vancouver, Canada to discuss and share the knowledge of the various measures to develop healthy bone and to prevent calcium-related diseases. This year, CBHI plans to hold ISACS in Manila, Philippines, which is not confirmed yet due to COVID-19 pandemic.

Share article on social media or email:

Take Forehead Temperatures from a Distance with New FDA-Cleared Noncontact IR Thermometer from Cole-Parmer


Get precise and quick forehead temperature measurements without contact when using the new FDA-cleared noncontact infrared (IR) thermometer.

Get precise and quick forehead temperature measurements without contact when using the new FDA-cleared noncontact infrared (IR) thermometer. It is designed to take the body temperature of a person regardless of room temperature and is easy to use. This versatile thermometer can also be used to take surface temperatures of an area or object such as food and can log 32 internal readings. This FDA-cleared IR thermometer is intended for industrial and office health screenings and monitoring.

When the thermometer is set to body mode, it can take the body temperature of a human being with a range from 89.6 to 108.5°F (32.0 to 42.5°C). Simply hold it 2” to 5.9″ (5 to 15 cm) away from the person to measure temperature on the forehead or behind the earlobe and then press the trigger to activate instrument. To take the temperature of a surface or object such as food, fluid or room temperature, switch the thermometer to surface mode. It features a wider temperature range from 32 to 140°F (0 to 60°C).

When this product is used for human body temperature measurement, it is only used as a reference for fever screening and cannot be used for medical identification. Use of this thermometer is not intended as a substitute for consultation with a healthcare professional.

This device is FDA cleared and within accordance of ASTM E1965-1998; EN 980: graphical symbols for use in the labeling of medical devices; EN 1041: information supplied by the manufacturer with medical devices; EN 60601-1: medical electrical equipment part 1: general requirements for safety (IEC:60601-1:1998); and EN 60601-1-2: medical electrical equipment part 1-2: general requirements for safety collateral standard electromagnetic compatibility requirements and test (IEC 60601-1-2:2001).

Cole-Parmer is a leading global manufacturer of Fluid Handling, Test & Measurement and Biosciences products, instrumentation, equipment and supplies. We are proven experts in the fields of temperature measurement, spectroscopy, fluid handling, sample preparation & handling and chromatography. Our products & instruments are used extensively in the industrial, pharmaceutical, life sciences, environmental and food & beverage industries. Our portfolio of unique industry-leading brands includes Argos Technologies®, Environmental Express®, Jenway®, Kinesis®, Masterflex®, Masterflex Ismatec®, Oakton®, PCRmax®, Stuart®, Techne®, TELOS®, Traceable®, and Vaplock™. We also partner with a number of key suppliers with industry-leading products.

Cole-Parmer is globally renowned for our highly-responsive customer service and experienced technical support representatives. Pipette Service and Calibration and Instrument Service facilities are also available in our North American and European locations.

                                                                 #####

Share article on social media or email:

More Joint Reconstruction Moving to Outpatient Setting


The latest evidence indicates that total reconstruction or replacement of the shoulder joint, much like knees and other joints, can be performed effectively in an outpatient setting, with outcomes often superior to those of joint replacements done when patients are in the hospital,

June 2020 – The latest evidence indicates that total reconstruction or replacement of the shoulder joint, much like knees and other joints, can be performed effectively in an outpatient setting, with outcomes often superior to those of joint replacements done when patients are in the hospital, says noted hand and upper limb orthopedic surgeon Alejandro Badia, MD. This avoids many hospital related issues, whether exposure to Covid19, or long standing hospital acquired infections such as MRSA.

Dr. Badia was referencing the latest study, published in the first-quarter 2020 issue of Ambulatory Surgery, indicating that total shoulder arthroplasty — joint reconstruction – can be conducted safely in the outpatient setting with what scientists call “a low complication rate and a high degree of patient satisfaction.” Any prosthetic joint replacement of the upper limb, such as thumb, wrist, elbow and of course, shoulder, is best suited for outpatient setting simply because the patient does not need to walk on the new joint. Going back to the comfort, and infection free environment, of home in a sling is preferable for many reasons.

The retrospective research, which reviewed the two-year outcomes of participating shoulder-joint patients, corroborates the results of earlier reports, including one that appeared in 2017 in the Journal of Shoulder and Elbow Surgery showing “no significant differences in the 30-day adverse event and readmission rates between outpatient and [hospital] inpatient total shoulder arthroplasty.”

And, it is not just shoulder patients benefitting from the outpatient trend. As early as 2006, scientists writing in the journal, Anesthesia & Pain Medicine, concluded that, with the appropriate post-operative analgesic regimen, a “subset of patients” could undergo total elbow arthroplasty as an ambulatory procedure.

“These studies are among a growing mound of evidence supporting the anecdotal experience of orthopedic surgeons who have reported performing total or partial joint arthroplasty on an outpatient basis safely and at much less cost to the patient AND overall healthcare system,” says Dr. Badia, author of the recently published book Healthcare in the Trenches. Dr. Badia is a specialist in treating joint disorders of the upper limb and is founder of the Florida-based Badia Hand to Shoulder Center and OrthoNOW®, a network of immediate care orthopedic clinics, where he is also Chief Medical Officer.

Despite the benefits of outpatient joint replacement, including lower infection risk and better recovery at home, Dr. Badia agrees with researchers that an effective outpatient orthopedic surgical program is not automatic. “It requires experienced orthopedic surgeons knowledgeable in the latest minimally-invasive approaches to joint replacement; specialized anesthesia protocols including regional block anesthesia, highly trained nurses and other dedicated clinical support staff; aggressive protocols for managing post-operative pain; careful, at-home patient monitoring; and selection and education of the ‘right patients’ for outpatient surgery.”

Dr. Badia says the “right patients” include those who are somewhat younger (under age 70), have a normal or only moderately elevated body mass index and are without any cardiopulmonary disorders or other major ailments. “Good candidates for outpatient joint replacement also need to have a positive mindset and be motivated participants in their recovery and typically have a good support system at home,” he says.

Noted for his application of innovative business principles and technology to enhance patient access to health services, Dr. Badia has been an early physician leader in moving joint replacement surgery to the outpatient setting and sees the trend as only accelerating in the future. A major obstacle continues to be the lack of CMS (Medicare) support for these procedures in stand-alone ASCs (ambulatory surgery centers) although that may change since, ironically, total knee replacements are now reimbursable in this environment, paving the way for other less challenging outpatient joint protocols.

According to a June 1, 2020 Orthopedic Joint Replacement Market Research Report, “the increasing prevalence of bone disease among the geriatric populations” globally will continue pushing demand for partial and total joint replacements. Even now, joint arthroplasties are among the most common surgical procedures in the United States, with more than a million performed annually.

Report authors cite continued development of new surgical techniques, including robotic surgery, and “patient-specific 3-D printed [joint] implants” as helping spur the market for partial and total joint replacements. Dr. Badia says such advancements will only enhance orthopedic surgeons’ capabilities in the future for performing outpatient joint replacements with effective long-term outcomes.

Meanwhile, he offers these tips to patients who have been told they require joint reconstruction and are considering outpatient surgery as an option:

  • Select a surgeon who is experienced in performing successful outpatient joint replacements. For example, results of a 2018 online survey of active members of the American Shoulder and Elbow Surgeons indicated that only about 21 percent of 179 respondents were performing total shoulder arthroplasties. Many times the surgeons are hospital affiliated and simply don’t have good access to this option.
  • Consider a facility where the surgeon is supported by a team trained specifically in joint replacement procedures and where patient education is emphasized.
  • Ask questions, especially concerning postoperative monitoring and pain management.
  • Have the proper mindset; determine to be a positive participant in the recovery process.
  • In a 2015 paper, the Foundation for Government Accountability (FGA) reported that “ambulatory surgical centers and recovery care centers have proven to be lower-cost, high quality care [facilities],” saving patients and employers as much as 60 percent in health care expenses, Dr. Badia says.

“My advice to patients – in the words made famous by Indiana Jones – ‘Choose wisely.’”

Alejandro Badia, MD, FACS, internationally renowned hand and upper-limb surgeon and founder of Badia Hand to Shoulder Center and OrthoNOW®, a walk-in orthopedic care clinic. He is a member of the American Society for Surgery of the Hand, American Association for Hand Surgery and the American Academy of Orthopedic Surgeons and an honorary member of many international professional hand societies. Dr. Badia specializes in treating all problems related to the hand and upper extremities, including trauma, sports injury, joint reconstruction, nerve injuries and arthroscopic surgeries. http://www.drbadia.com http://www.OrthoNOWcare.com

Share article on social media or email:

The Centre For Mindfulness Studies Launches a New Meditation Practice Support Mobile App To Help Those Who Are Stressed, Depressed and Anxious


The Centre for Mindfulness Studies, Canada’s leading service delivery and professional training organization in mindfulness-based interventions for mental health, today announced the launch of a new free mobile app, available on iOS, Android and the web. In one convenient place, the app contains all the mindfulness-based meditations and supports needed for individuals to continue to build their practice for mental health and well-being.

The Centre for Mindfulness Studies’ 8-week online group programs are delivered by healthcare professionals to those suffering from stress, depression, and anxiety. The app was developed to support a program participant’s ongoing mindfulness-based practice. This app provides all of the meditations that are used in the following programs offered: Mindfulness-Based Cognitive Therapy (MBCT), Mindfulness-Based Stress Reduction (MBSR), and Mindful Self-Compassion (MSC). The programs are evidence-based, peer-reviewed, and effective in treating mental health concerns.

“More than 10,000 people have taken a mindfulness-based program for their mental health through the Centre and this new app will be an easily accessible resource for them to continue to benefit from their practice,” says Barry Patterson, Executive Director. “These are challenging times weighing heavily on people’s mental health and for those looking towards mindfulness the app will introduce them to the foundational meditations of our programs.”

Centre for Mindfulness Studies app features:

  • Save (or “favourite”) meditations for quick access. Download meditations so that they can be used offline
  • Access and filter meditations by program and duration (MBCT, MBSR, MSC)
  • Scroll through our MindFeed notification board for mindfulness news and content from the Centre
  • Schedule meditations and receive a notification when it is time to meditate

To download the app go to https://www.mindfulnessstudies.com/get-the-app/. The Centre is also offering a $100 savings on mindfulness programs in June, July and August find out more here.

About the Centre for Mindfulness Studies

The Centre for Mindfulness Studies is a not-for-profit, charitable social enterprise founded in 2011. It is the Canadian leader in developing and providing professional mindfulness programs for mental health. Our goal is to ensure access to those most in need, to lead change and bring mindfulness as a healthcare service to diverse populations. To learn more about us visit http://www.mindfulnessstudies.com.

Media Contact: Michelle Ragno, michelle@mindfulnessstudies.com

Share article on social media or email: